Navigation Links
ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
Date:4/4/2011

IRVINE, Calif., April 4, 2011 /PRNewswire/ --ChromaDex Corporation (OTCBB: CDXC),an innovative natural products company that provides proprietary, science-based solutions and ingredients, today announced that Curtis A. Lockshin, Ph.D., was appointed to its Board of Directors.

Dr. Lockshin currently serves as a Director of Sorrento Therapeutics and the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Winston Pharmaceuticals. In addition to his board positions, he serves as a consultant to private companies in healthcare and biotechnology. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.

"Dr. Lockshin's deep experience with an array of science-based, regulated companies brings valuable perspective to our board," said Frank Jaksch, CEO and co-founder of ChromaDex. "As we convert our knowledge of natural compounds into innovative commercial products and applications targeted at the nutraceutical, food and beverage, cosmetic and pharmaceutical markets, we are committed to strengthening our management team and our board with the experience needed to reinforce our dedication to the science behind our natural ingredients."

About ChromaDex

ChromaDex™ is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has a strong pipeline of new compounds, including its pTeroPure™ pterostilbene on which it has worldwide, exclusive rights to patents pending.  ChromaDex is a publicly-traded life-sciences company (OTC stock symbol CDXC.OB).

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the company's Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Inquiries
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com

ChromaDex Contact
Jenny Robles
949-419-0288
jennyr@chromadex.com

Media Contact
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com


'/>"/>
SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President
2. ChromaDex Commences a Clinical Trial on pTeroPureā„¢ Pterostilbene
3. ChromaDex Launches pTeroPure Pterostilbene
4. ChromaDex Announces 2008 Year End Financial Results
5. ChromaDex Announces Second Quarter 2008 Financial Results
6. BioStorage Technologies Appoints New Director of Business Development for European Operations
7. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
8. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
9. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
10. Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality
11. OncoSec Medical Appoints Punit Dhillon as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):